Novastan Multidos (Argatroban Monohydrate)

Novastan Multidos, a direct thrombin inhibitor, is used in clinical settings where anticoagulation is required without heparin.

• Heparin‑induced thrombocytopenia (HIT): provides effective anticoagulation when heparin is contraindicated.
• Percutaneous coronary intervention (PCI): maintains anticoagulation throughout the interventional procedure.
• Cardiac surgery requiring anticoagulation: supports anticoagulation during cardiopulmonary bypass and related surgical contexts.

• Argatroban binds directly to the active site of thrombin (factor IIa), blocking its ability to convert fibrinogen to fibrin. By inhibiting thrombin, it prevents clot formation and propagation without relying on antithrombin III, offering a rapid and reversible anticoagulant effect that is primarily cleared by hepatic metabolism.

Common Side Effects

• Bleeding: minor to moderate hemorrhage at infusion sites or mucosal surfaces.
• Thrombocytopenia: reduction in platelet count observed during therapy.
• Elevated liver enzymes: transient increases in ALT or AST.
• Nausea or headache: mild gastrointestinal or neurologic discomfort.
• Fever: low‑grade temperature elevation.

Serious or Rare Side Effects

• Major bleeding: life‑threatening hemorrhage requiring medical intervention.
• Hepatic failure: severe liver dysfunction in susceptible patients.
• Anaphylaxis: acute hypersensitivity reaction with respiratory compromise.
• Hemolysis: destruction of red blood cells leading to anemia.
• Thrombotic events: paradoxical clot formation in rare cases.

Novastan Multidos requires careful clinical monitoring to ensure safe use.

• Coagulation monitoring: regularly assess activated clotting time (ACT) or aPTT.
• Liver function: evaluate hepatic enzymes before and during therapy.
• Dose adjustment: reduce dose in patients with moderate to severe hepatic impairment.
• Active bleeding: avoid use in patients with uncontrolled hemorrhage.
• Pregnancy and lactation: safety not established; use only if benefit outweighs risk.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Argatroban may interact with other agents that affect hemostasis or hepatic metabolism.

Major Interactions (Avoid)

• Concurrent anticoagulants (e.g., warfarin, heparin): markedly increased bleeding risk.
• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): elevate argatroban plasma levels.
• Antiplatelet drugs (e.g., aspirin, clopidogrel) at full dose: synergistic hemorrhagic effect.

Moderate Interactions (Monitor Closely)

• Mild CYP3A4 inhibitors (e.g., fluconazole): may modestly raise drug concentration.
• NSAIDs or other non‑steroidal anti‑inflammatories: increase minor bleeding tendency.
• Fibrinolytic agents (e.g., alteplase): additive anticoagulant effect requiring close observation.